Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utiliz...
Protagonist Therapeutics is a clinical stage bi...
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driv...
Tabula Rasa HealthCare (TRHC) is a leader in pr...
We are a patient-centric, clinical-stage biopharmaceutical company dedicated to br...
We are a patient-centric, clinical-stage biopha...
Veracyte is a leading genomic diagnostics company that is fundamentally improving ...
Veracyte is a leading genomic diagnostics compa...
Join the National Investor Network and get the latest information with your interests in mind.